Argipressin acetate (Embesin®)is indicated for the treatment of catecholamine refractory hypotension following septic shock in patients older than 18 years. A catecholamine refractory hypotension is present if the mean arterial blood pressure cannot be stabilised to target despite adequate volume substitution and application of catecholamines.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||16/09/2019|
|Rapid review completed||11/10/2019|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that argipressin acetate (Embesin®) not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.